[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-344211-105":59,"doc-detail-344211-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","quantifying-tumor-specificity-using-bayesian-probabilistic-modeling-for-drug-and-immunotherapeutic-target-discovery","Quantifying tumor specificity using Bayesian probabilistic modeling for drug and immunotherapeutic target discovery","","Li et al. introduce BayesTS, a tunable Bayesian tumor specificity index designed to support safer immunotherapy and drug target discovery. The method integrates heterogeneous evidence types, including gene expression, immunostaining-based protein detection, and tissue distribution, while explicitly accounting for inferential uncertainty. By learning disease-specificity across genes through hierarchical Bayesian modeling, BayesTS improves cross-modality agreement, outperforms alternative target selection strategies, and can be extended to new modalities and unconventional target definitions such as splicing events.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/quantifying-tumor-specificity-using-bayesian-probabilistic-modeling-for-drug-and-immunotherapeutic-target-discovery/344211/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/quantifying-tumor-specificity-using-bayesian-probabilistic-modeling-for-drug-and-immunotherapeutic-target-discovery/344211.png","ImageObject",300,407,{"name":92,"@type":93},"Clementine","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What problem does BayesTS address in immunotherapy target selection?","Question",{"text":113,"@type":114},"BayesTS addresses the challenge of selecting immunotherapeutic targets with tumor-specific expression while avoiding off-target toxicity. It targets limitations of current approaches that rely on arbitrary cutoffs across multiple modalities.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How does BayesTS integrate evidence to quantify tumor specificity?",{"text":118,"@type":114},"BayesTS uses a hierarchical Bayesian modeling framework that jointly evaluates complementary molecular measurements from healthy tissues. It integrates protein and gene expression evidence and includes tunable parameters to moderate tissue essentiality.",{"name":120,"@type":111,"acceptedAnswer":121},"Can BayesTS be adapted beyond standard gene or protein targets?",{"text":122,"@type":114},"Yes. The approach can be extended to unconventional targets such as splicing antigens and to combinatorial target pairs, enabling more specific therapy targets.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},344211,1790468357,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":56,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1374391974564,"https://ap-avatar.wpscdn.com/avatar/14000253aa45c000a9e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779874745381141002","Article  \nQuantifying tumor speciﬁcity using Bayesian probabilistic modeling for drug and immunotherapeutic target discovery  \nGraphical abstract  \nAuthors  \nGuangyuan Li, Daniel Schnell, Anukana Bhattacharjee,  \nMark Yarmarkovich, Nathan Salomonis  \nCorrespondence  \n[guangyuan.li@nyulangone.org](guangyuan.li@nyulangone.org)  \nIn brief  \nLi et al. introduce BayesTS, a Bayesian tumor speciﬁcity index that integrates multiple evidence types, including gene expression, protein detection by immunostaining, and tissue distribution, to prioritize targets for immunotherapy. BayesTS offers ﬂexible tuning for safe target selection in cancer that can be extended to nearly any modality.  \nd BayesTS is a tunable approach to estimate tumor speciﬁcity from omics data  \nd BayesTS leverages multi-omic evidence, overcoming current limitations  \nd This approach can be adapted to diverse molecular modalities and questions  \nd Early embryonic, placental, and germline genes exhibit high tumor speciﬁcity  \nLi et al., 2024, Cell Reports Methods 4, 100900  \nNovember 18, 2024 ª 2024 The Author(s) . Published by Elsevier Inc.  \n[https://doi.org/10.1016/j.crmeth.2024.100900](https://doi.org/10.1016/j.crmeth.2024.100900)  \nll  \nll  \nOPEN ACCESS  \nArticle  \nQuantifying tumor speciﬁcity using Bayesian probabilistic modeling for drug and immunotherapeutic target discovery  \nGuangyuan Li,1,2,3,4,* Daniel Schnell,1 Anukana Bhattacharjee,1 Mark Yarmarkovich,3 and Nathan Salomonis1,2  \n1Division of Biomedical Informatics, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH 45229, USA  \n2Department of Biomedical Informatics, College of Medicine, University of Cincinnati, Cincinnati, OH 45267, USA  \n3Perlmutter Cancer Center, New York University Grossman School of Medicine, New York, NY, USA  \n4Lead contact  \n*Correspondence: [guangyuan.li@nyulangone.org](guangyuan.li@nyulangone.org)  \n[https://doi.org/10.1016/j.crmeth.2024.100900](https://doi.org/10.1016/j.crmeth.2024.100900)  \nMOTIVATION Selecting immunotherapeutic targets with tumor-speciﬁc expression is crucial for effective immunotherapy and minimized off-target toxicity. Current strategies often rely on arbitrary cutoffs across multiple modalities, introducing subjectivity and hindering cross-study consistency. We present BayesTS, a Bayesian index that ﬂexibly integrates diverse molecular and tissue data while accounting for inferential uncertainty. BayesTS accurately captures expression proﬁles across modalities and can identify both previously unknown and established targets. Its adaptability extends to unconventional targets, such as splicing events, offering a valuable tool for advancing cancer therapy development.  \nSUMMARY  \nIn diseases such as cancer, the design of new therapeutic strategies requires extensive, costly, and unfortunately sometimes deadly testing to reveal life threatening off-target effects. We hypothesized that the diseasespeciﬁcity of targets can be systematically learned for all genes by jointly evaluating complementary molecular measurements of healthy tissues using a hierarchical Bayesian modeling approach. Our method, BayesTS, integrates protein and gene expression evidence and includestunable parameters to moderate tissue essentiality. Applied to all protein coding genes, BayesTS outperforms alternative strategies to deﬁne therapeutic targets and nominates previously unknown targets while allowing for incorporation of new types of modalities. To expand target repertoires, we show that extension of BayesTS to splicing antigens and combinatorial target pairs results in more speciﬁc targets for therapy. We expect that BayesTS will facilitate improved target prioritization for oncology drug development, ultimately leading to the discovery of more effective and safer treatments.  \nINTRODUCTION  \nTumor cells undergo extensive genetic and genomic alterations that substantially alter their cell growth and metabolism.1 ,2 While advantageous for tumor survival, these alteration","cbCaibX4JvPIjrqW","https://ap.wps.com/l/cbCaibX4JvPIjrqW","pdf",4087011,"English","# Motivation\n# Summary\n# Introduction","[{\"question\":\"What problem does BayesTS address in immunotherapy target selection?\",\"answer\":\"BayesTS addresses the challenge of selecting immunotherapeutic targets with tumor-specific expression while avoiding off-target toxicity. It targets limitations of current approaches that rely on arbitrary cutoffs across multiple modalities.\"},{\"question\":\"How does BayesTS integrate evidence to quantify tumor specificity?\",\"answer\":\"BayesTS uses a hierarchical Bayesian modeling framework that jointly evaluates complementary molecular measurements from healthy tissues. It integrates protein and gene expression evidence and includes tunable parameters to moderate tissue essentiality.\"},{\"question\":\"Can BayesTS be adapted beyond standard gene or protein targets?\",\"answer\":\"Yes. The approach can be extended to unconventional targets such as splicing antigens and to combinatorial target pairs, enabling more specific therapy targets.\"}]","Quantifying tumor specificity using Bayesian probabilistic modeling for drug and immunotherapeutic target discovery | PDF",1790053224,48,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c58285052940b2ccc2fa5d3e366c14f9.webp",983,1276,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/46ba682666acc932893e6990c77b64dd.webp",982,1275,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/86fbfc1f133fa6b1811dd21d57082bc6.webp",981,1273,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5482e21f45042795d5f76302a8fce725.webp",980,1272]